BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia

Core Insights - The presentation focuses on encaleret, a small molecule being developed for autosomal dominant hypocalcemia type 1 (ADH1) [2][3] - The webinar includes insights from key figures in the field, including Dr. Rachel Gafni and Dr. Scott Adler, who will discuss the clinical development program for encaleret [3] Market Opportunity - The company aims to highlight the market potential for ADH1 and the patient experience associated with the condition [4]